Hormonal
Treatment with GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produces substantial body weight loss (exceeding 15%) and improves glucose control, leading to type 2 diabetes prevention and possible disease remission.
If you have obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or liraglutide) are highly effective treatments that can help you lose more than 15% of your body weight and improve blood sugar control. This can potentially lead to remission of type 2 diabetes. While lifestyle changes are important, they are often not enough on their own to maintain weight loss or prevent diabetes progression, making these medications a key part of modern management.
Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications.
Why this rating
Based on multiple RCTs, meta-analyses, and expert group recommendations cited in the paper.
Source
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01615-5
More from this paper
- GLP-1 receptor agonists improve cardiovascular outcomes by reducing major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with type 2 diabetes and established cardiovascular disease.Strong
- GLP-1 receptor agonists improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing liver fat content, liver stiffness, and liver enzymes (ALT, AST).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →